Markets closed

AstraZeneca PLC Ordinary Shares

AZN · NYSE

Symbol: AZN
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Key Issues

Bullish view

The Amgen-AstraZeneca IMDELLTRA-Imfinzi combination produced a survival benefit in a Phase 3 extensive-stage small-cell lung-cancer study, while AstraZeneca also reported a Phase III small-cell lung-cancer survival win. Those results support continued pipeline and franchise value.

Bearish view

A reported late-stage oncology trial miss caused after-hours weakness, and an executive was described as disappointed. Repeated setbacks could undermine confidence in the pipeline and keep valuation under pressure.

Analyst Consensus

See all

Buy

12 analysts

$164

Current

—

Low

$215

Average

—

High

Average target implies +30.97% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Novartis AGNVS · NYSE

$138.991.33%

Novo Nordisk A/SNVO · NYSE$43.450.88%

Abbott LaboratoriesABT · NYSE$103.091.12%

Pfizer, Inc.PFE · NYSE$27.600.43%

Analyst Consensus

Buy

12 analysts

$164

Current

—

Low

$215

Average

—

High

Average target implies +30.97% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 12 analysts, with a mean target of $214.5; the low and high targets are not available, so target clustering and the width of the spread cannot be established. Among explicitly named actions, RBC Capital reaffirmed Buy, making it more constructive than HSBC, whose supplied snippet says it downgraded AstraZeneca to Hold from Buy and set a 13,750 GBp target. No analyst is identified as the most bullish by target, and no complete ranking is available. The evidence does not establish a clear direction for revisions during the week: it records both RBC’s reaffirmation and HSBC’s downgrade, with no dates or target history sufficient to quantify the change.